MX2024003921A - Variantes de la reticulocalbina-3 (rcn3) y tratamiento del asma con antagonistas del receptor alfa de la interleucina-4 (il4r). - Google Patents

Variantes de la reticulocalbina-3 (rcn3) y tratamiento del asma con antagonistas del receptor alfa de la interleucina-4 (il4r).

Info

Publication number
MX2024003921A
MX2024003921A MX2024003921A MX2024003921A MX2024003921A MX 2024003921 A MX2024003921 A MX 2024003921A MX 2024003921 A MX2024003921 A MX 2024003921A MX 2024003921 A MX2024003921 A MX 2024003921A MX 2024003921 A MX2024003921 A MX 2024003921A
Authority
MX
Mexico
Prior art keywords
rcn3
asthma
il4r
treatment
reticulocalbin
Prior art date
Application number
MX2024003921A
Other languages
English (en)
Spanish (es)
Inventor
Charles Paulding
Shan Chen
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2024003921A publication Critical patent/MX2024003921A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2024003921A 2021-09-30 2022-09-27 Variantes de la reticulocalbina-3 (rcn3) y tratamiento del asma con antagonistas del receptor alfa de la interleucina-4 (il4r). MX2024003921A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163250546P 2021-09-30 2021-09-30
PCT/US2022/077088 WO2023056254A1 (en) 2021-09-30 2022-09-27 Reticulocalbin-3 (rcn3) variants and treatment of asthma with interleukin-4 receptor alpha (il4r) antagonists

Publications (1)

Publication Number Publication Date
MX2024003921A true MX2024003921A (es) 2024-04-22

Family

ID=83902767

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024003921A MX2024003921A (es) 2021-09-30 2022-09-27 Variantes de la reticulocalbina-3 (rcn3) y tratamiento del asma con antagonistas del receptor alfa de la interleucina-4 (il4r).

Country Status (9)

Country Link
US (1) US20230151426A1 (https=)
EP (1) EP4409037A1 (https=)
JP (1) JP2024536001A (https=)
KR (1) KR20240067064A (https=)
CN (1) CN117957332A (https=)
CA (1) CA3230302A1 (https=)
IL (1) IL311480A (https=)
MX (1) MX2024003921A (https=)
WO (1) WO2023056254A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
WO2011156000A2 (en) * 2010-06-07 2011-12-15 Aerovance, Inc. Use of il-4/il-13 antagonists to treat eosinophilic disorders
AR098155A1 (es) * 2013-10-23 2016-05-04 Genentech Inc Métodos para diagnosticar y tratar trastornos eosinofílicos

Also Published As

Publication number Publication date
CN117957332A (zh) 2024-04-30
EP4409037A1 (en) 2024-08-07
KR20240067064A (ko) 2024-05-16
CA3230302A1 (en) 2023-04-06
JP2024536001A (ja) 2024-10-04
IL311480A (en) 2024-05-01
WO2023056254A1 (en) 2023-04-06
AU2022356375A1 (en) 2024-03-14
US20230151426A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
Martínez‐Jauand et al. Pain sensitivity in fibromyalgia is associated with catechol‐O‐methyltransferase (COMT) gene
Morgenstern et al. The challenge of defining “ultra‐high‐risk” neuroblastoma
Mewton et al. The effectiveness of internet cognitive behavioural therapy for generalized anxiety disorder in clinical practice
Galluzzo et al. IL12B (p40) gene polymorphisms contribute to ustekinumab response prediction in psoriasis
US12146193B2 (en) Methods and compositions relating to OPRM1 DNA methylation for personalized pain management
ZA202100296B (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
Iqbal et al. Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era
AR098155A1 (es) Métodos para diagnosticar y tratar trastornos eosinofílicos
ATE419390T1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
Terrazzino et al. Genetic determinants of chronic oxaliplatin‐induced peripheral neurotoxicity: a genome‐wide study replication and meta‐analysis
Stanzani et al. Radioresistance of mesenchymal glioblastoma initiating cells correlates with patient outcome and is associated with activation of inflammatory program
Grinfeld et al. A common novel splice variant of SLC 22 A 1 (OCT 1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia
Clukay et al. DNA methylation of methylation complex genes in relation to stress and genome‐wide methylation in mother–newborn dyads
Marcath et al. Genetic variation in EPHA contributes to sensitivity to paclitaxel‐induced peripheral neuropathy
Song et al. Association between single nucleotide polymorphisms in XRCC3 and radiation-induced adverse effects on normal tissue: a meta-analysis
AU2003302732A8 (en) Method for identifying risk of breast cancer and treatments thereof
Isselhard et al. Psychological distress and decision‐making factors for prophylactic bilateral mastectomy in cancer‐unaffected BRCA1/2 pathogenic variant carriers
Cassaday et al. Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD
Alonso‐Dominguez et al. PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase
MX2024003921A (es) Variantes de la reticulocalbina-3 (rcn3) y tratamiento del asma con antagonistas del receptor alfa de la interleucina-4 (il4r).
EA202192176A1 (ru) Нарушения, опосредованные интерфероном i типа
Hyman et al. Tumor Genetic Screening Programs: A Call to Action.
Andolina et al. Practice patterns of physician treatment for pediatric chronic myelogenous leukemia
IN2012DN06571A (https=)
EA202090439A1 (ru) Способы и материалы для оценки и лечения рака